Category - News

Developments

Avadel Pharma completes enrollment in Phase 3 narcolepsy trial

Avadel Pharmaceuticals (NASDAQ:AVDL) completed enrollment in its pivotal trial assessing FT218 for excessive daytime sleepiness and cataplexy in patients with narcolepsy. The Phase 3 study, called REST-ON, enrolled 212...

December 17, 2019

Markets

SVB Leerink halves Adamas Pharma PT to $6

SVB Leerink lowered its price target for Adamas Pharmaceuticals (NASDAQ:ADMS) to $6 from $13, saying the mixed Phase 3 INROADS data are not good enough. In afternoon trading on Dec. 17, the stock was quoted at $4.15...

December 17, 2019

Developments

Pacira reports positive Phase 3 results for long-acting local analgesic in pediatric patients

Pacira BioSciences (NASDAQ:PCRX) reported positive results from its Phase 3 study of EXPAREL in pediatric patients undergoing spinal or cardiac surgeries. EXPAREL is a non-opioid, single-dose, long-acting local...

December 17, 2019

Developments

Eiger initiates rolling NDA for progeria drug candidate

Eiger BioPharmaceuticals (NASDAQ:EIGR) initiated a rolling NDA submission to the FDA for lonafarnib for the treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies. Progeria is an extremely rare...

December 17, 2019

Developments

Kamada enrolls first patient in Phase 3 alpha-1 antitrypsin deficiency trial

Kamada (NASDAQ, TASE:KMDA) randomized the first patient in a pivotal clinical trial evaluating its inhaled alpha-1 antitrypsin (AAT) therapy for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is an...

December 17, 2019

Markets

Analysts up ImmunoGen PTs on FDA accelerated approval pathway

Analysts for H.C. Wainwright and SVB Leerink raised their price targets for ImmunoGen (NASDAQ:IMGN) after the FDA advised that a new single-arm study in platinum-resistant ovarian cancer (prOC) could support accelerated...

December 17, 2019

Executive Moves

Indalo appoints healthcare industry veteran Michael Heffernan as board chair

Closely-held Indalo Therapeutics appointed Michael Heffernan as chair of its board of directors. “Indalo’s unique approach to treating fibrosis, combined with a highly experienced team and world-class financial backers...

December 17, 2019

Developments

Kane Biotech launches anti-biofilm shampoo consumer product test

Kane Biotech (TSX-V:KNE) launched a consumer product test to evaluate the efficacy of its new shampoo on dermatitis and dandruff. Research indicates that microbial biofilms may aggravate symptoms associated with...

December 16, 2019

Developments

iBio reports progress on bio-better rituximab collaboration

At last week’s Antibody Engineering & Therapeutics conference in San Diego, CA, iBio (NYSE AMERICAN:IBIO) presented its glycan engineering technologies and plant-based manufacturing platform as a means to rapidly...

December 16, 2019

Developments

OncoSec presents interim Phase 2 data in metastatic triple negative breast cancer

OncoSec Medical (NASDAQ:ONCS) presented interim results from KEYNOTE-890, an ongoing Phase 2 study of its TAVO drug candidate in combination with KEYTRUDA in patients with metastatic, chemotherapy-refractory triple...

December 13, 2019

Category - News

Avadel Pharma completes enrollment in Phase 3 narcolepsy trial

SVB Leerink halves Adamas Pharma PT to $6

Pacira reports positive Phase 3 results for long-acting local analgesic in pediatric patients

Eiger initiates rolling NDA for progeria drug candidate

Kamada enrolls first patient in Phase 3 alpha-1 antitrypsin deficiency trial

Analysts up ImmunoGen PTs on FDA accelerated approval pathway

Indalo appoints healthcare industry veteran Michael Heffernan as board chair

Kane Biotech launches anti-biofilm shampoo consumer product test

iBio reports progress on bio-better rituximab collaboration

OncoSec presents interim Phase 2 data in metastatic triple negative breast cancer

General

More